New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent ...
We work right across the cancer research pathway with strengths ranging from cell biology to healthcare research. Thanks to the brilliant advances made over the past 40 years, cancer survival rates ...